Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Scherr, Adolfo J O ^a   Lima, Joao Paulo S N ^a   Sasse, Emma C ^a   Lima, Carmen S P ^a   Sasse, André D ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antineoplastic agentsdrug therapyrenal cell carcinoma; meta analysis

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; FLUOROURACIL; INTERLEUKIN 2; MEDROXYPROGESTERONE; THALIDOMIDE;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HUMAN; INJECTION SITE PAIN; KIDNEY CANCER; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SKIN INDURATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; IMMUNOTHERAPY; KIDNEY TUMOR; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SURVIVAL;

CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 79953184330     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-115     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 1986, 27:291-301.
3. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993, 11:1368-1375.
4. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000, 6(Suppl 1):S55-57.
5. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E, Minervini S, Zanollo A, Fontanella U, Longo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987, 138:1379-1381.
6. Naito S, Kumazawa J, Omoto T, Iguchi A, Sagiyama K, Osada Y, Hiratsuka Y. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol 1997, 4:8-12.
7. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-1222.
8. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005, 92:843-846.
9. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
10. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
11. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. Systematic reviews in health care: Metaanalisys in context 2001, London: BMJ Publication Group, Egger M, Smith GD, Altman DG, 2.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
14. Aitchison M, Bray C, Van Poppel H, Sylvester R, Graham J, Innes C, McMahon L, Vasey PA. Preliminary results from a randomized phase III trial of adjuvant interleukin-2, interferon alpha and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). 2008 ASCO Annual Meeting; Chigaco 2008, American Society of Clinical Oncology.
15. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-3140.
16. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996, 77:2560-2566.
17. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363:594-599.
18. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425-431.
19. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-154.
20. Passalacqua R, Buzio C, Buti S, Labianca R. Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer. A Phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol 2007, 25.
21. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009, 73:337-341.
22. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006, 33:576-582.
23. Kapoor A, Gharajeh A, Sheikh A, Pinthus J. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol 2009, 16(Suppl 1):S60-66.